22401 HW6

Bin Yu

Mar 05, 2025

Question 1

(a)

The 2x2 table for recurrence is given by:

. tabulate recur trt

recur	 	trt 0	1		Total
0 1		358 164	408 112	•	766 276
Total		522	520	 	1,042

Odds Ratio (OR):

The odds of recurrence in the tamoxifen group are

$$Odds_1 = \frac{112}{408} \approx 0.2745,$$

and in the placebo group

$$Odds_0 = \frac{164}{358} \approx 0.4581.$$

Thus, the odds ratio is

$$\mathrm{OR} = \frac{0.2745}{0.4581} \approx 0.5992.$$

Risk Difference (RD):

The risk of recurrence for the placebo group is

$$p_0 = \frac{164}{522} \approx 0.3141,$$

and for the tamoxifen group is

$$p_1 = \frac{112}{520} \approx 0.2154.$$

Hence, the risk difference is

$$\Delta = p_1 - p_0 \approx 0.2154 - 0.3141 \approx -0.0987.$$

This indicates a reduction of about 9.9 percentage points in recurrence with tamoxifen.

Relative Risk is given by:

$$RR = p_1/p_0 = \frac{0.2154}{0.3141} \approx 0.6858$$

The 2x2 table for death is presented below:

tabulate dead trt

	tr	rt	
dead	0	1	Total
	+		+
0	337	368	705
1	185	152	337
	+		+
Total	522	520	1,042

Odds Ratio (OR):

The odds of death in the tamoxifen group are

$$Odds_1 = \frac{152}{368} \approx 0.4130,$$

and in the placebo group

$$Odds_0 = \frac{185}{337} \approx 0.5490.$$

Thus, the odds ratio is

$$OR = \frac{0.4130}{0.5490} \approx 0.7523.$$

Risk Difference (RD):

The risk of death in the placebo group is

$$p_0 = \frac{185}{522} \approx 0.3544,$$

and in the tamoxifen group is

$$p_1 = \frac{152}{520} \approx 0.2923.$$

The risk difference is therefore

$$\Delta = p_1 - p_0 \approx 0.2923 - 0.3544 \approx -0.0621.$$

This shows a reduction of about 6.2 percentage points in the risk of death with tamoxifen.

Relative Risk is given by:

$$RR = p_1/p_0 = \frac{0.2923}{0.3544} \approx 0.8248$$

(b)

Endpoint 1: Disease Recurrence Stata Output

. logit recur trt, or

Iteration 0: $\log likelihood = -602.37472$

Iteration 1: log likelihood = -595.83931
Iteration 2: log likelihood = -595.81568
Iteration 3: log likelihood = -595.81568

Logistic regression Number of obs = 1,042LR chi2(1) = 13.12

Prob > chi2 = 0.0003

recur | Odds Ratio Std Err z P>|z| [95\% Conf Interval]

recur	Odds Ratio					Interval]
trt	•	.0853156	-3.60	0.000	.4533232	

Note: _cons estimates baseline odds.

Hypothesis Test

We test the null hypothesis that treatment has no effect on disease recurrence:

$$H_0: OR = e^{\beta_1} = 1$$
 (equivalently, $\beta_1 = 0$).

From the output, the estimated odds ratio is 0.5992348. Converting to the log scale:

$$\hat{\beta} = \ln(0.5992348) \approx -0.512.$$

The Wald test statistic is given by

$$Z = \frac{\hat{\beta}}{s.e.(\hat{\beta})} = -3.60,$$

with a corresponding p-value < 0.001.

Interpretation

Since the p-value is below 0.05, we reject the null hypothesis. This indicates that tamoxifen treatment is significantly associated with a reduction in disease recurrence. Therefore, the odds of recurrence in the tamoxifen group are approximately 60% compared to those in the placebo group.

Death

Stata Output

. logit dead trt, or

Iteration 0: log likelihood = -655.85351
Iteration 1: log likelihood = -653.55678
Iteration 2: log likelihood = -653.55533
Iteration 3: log likelihood = -653.55533

Logistic regression Number of obs = 1,042

LR chi2(1) = 4.60Prob > chi2 = 0.0320

| dead | Odds Ratio Std. Err. z P>|z| [95\% Conf. Interval]

trt	.7524089	.1000141	-2.14	0.032	.5798395	.9763377
_cons	.5489614	.0502315	-6.55	0.000	.4588328	.656794

Note: _cons estimates baseline odds.

Hypothesis Test

We now test the null hypothesis that treatment has no effect on death:

$$H_0: OR = e^{\beta_1} = 1$$
 (i.e., $\beta_1 = 0$).

The estimated odds ratio is 0.7524089, which on the log scale gives:

$$\hat{\beta} = \ln(0.7524089) \approx -0.285.$$

The test statistic is

$$Z = \frac{\hat{\beta}}{s.e.(\hat{\beta})} \approx -2.14,$$

with a p-value of 0.032.

Interpretation

Since the p-value is below 0.05, we reject H_0 . This indicates that tamoxifen treatment is significantly associated with a reduction in death. Specifically, the odds of death in the tamoxifen group are about 75% compared to those in the placebo group.

(c)

We extend the logistic regression model for the recurrence endpoint by including additional continuous covariates: age at diagnosis (age), body mass index (bmi, in kg/m²), and tumor size (tumsiz, in mm). The Stata output below provides the odds ratios and associated tests for each predictor.

Stata Output

logit recur trt age bmi tumsiz, or

Iteration 0: log likelihood = -602.37472
Iteration 1: log likelihood = -583.84502
Iteration 2: log likelihood = -583.66653
Iteration 3: log likelihood = -583.66651

Logistic regression Number of obs = 1,042 LR chi2(4) = 37.42 Prob > chi2 = 0.0000 Log likelihood = -583.66651 Pseudo R2 = 0.0311

recur | Odds Ratio Std. Err. 7. P>|z| [95\% Conf. Interval] .6077191 .0876392 -3.450.001 .4580902 .8062221 trt | .9744114 .007044 -3.59.9607027 .9883156 age | 0.000 bmi | 1.020568 .0134689 1.54 0.123 .994508 1.047311 tumsiz | 1.018924 .0062295 3.07 0.002 1.006787 1.031207 _cons | .6972886 .3368405 -0.75 0.455 .2705335 1.797232

Note: _cons estimates baseline odds.

Hypothesis Tests and Interpretations

For each predictor, we test the null hypothesis $H_0: \beta_i = 0$ (equivalently, OR = 1) using the Wald test.

• Treatment (trt):

OR = 0.6077 with a 95% CI of (0.4581, 0.8062), z = -3.45, and p = 0.001.

Interpretation: Holding age, BMI, and tumor size constant, patients receiving tamoxifen have odds of recurrence that are multiplied by 0.6077 relative to those on placebo. In other words, tamoxifen is associated with a 39.2% reduction in the odds of recurrence (since $1 - 0.6077 \approx 0.3923$). This effect is significant.

• Age (age):

OR = 0.9744 with a 95% CI of (0.9607, 0.9883), z = -3.59, and p < 0.001.

Interpretation: Controlling for treatment, BMI, and tumor size, each additional year of age multiplies the odds of recurrence by 0.9744. That is, for every extra year, the odds of recurrence decrease by about 2.56% (since $1 - 0.9744 \approx 0.0256$). This effect is significant.

• Body Mass Index (bmi):

OR = 1.0206 with a 95% CI of (0.9945, 1.0473), z = 1.54, and p = 0.123.

Interpretation: Holding the other variables constant, a one unit increase in BMI multiplies the odds of recurrence by 1.0206. That is, for every extra BMI, the odds of recurrence increase by about 2.06% increase. However, this effect is not statistically significant.

• Tumor Size (tumsiz):

OR = 1.0189 with a 95% CI of (1.0068, 1.0312), z = 3.07, and p = 0.002.

Interpretation: Controlling for treatment, age, and BMI, each additional millimeter in tumor size multiplies the odds of recurrence by 1.0189. That is, for every extra tumor size, the odds of recurrence increase by about 1.89% increase. This effect is significant.

(d)

Change the variable to dead:

Stata Output

logit dead trt age bmi tumsiz, or

Iteration 0: log likelihood = -655.85351Iteration 1: log likelihood = -629.67686Iteration 2: log likelihood = -629.48063Iteration 3: log likelihood = -629.48058

Logistic regression Number of obs = 1,042 LR chi2(4) = 52.75 Prob > chi2 = 0.0000 Log likelihood = -629.48058 Pseudo R2 = 0.0402

dead | Odds Ratio Std. Err. z P>|z| [95\% Conf. Interval] .7229534 .0986705 -2.380.017 .5532688 trt | .9446793 age | 1.031604 .0074625 4.30 0.000 1.017081 1.046334 1.023056 .0128355 1.82 0.069 .9982053 1.048525 bmi | tumsiz | 1.027569 .0061317 4.56 0.000 1.015621 1.039658 .0290188 .014626 -7.02 0.000 .0108058 .0779292 _cons |

Note: _cons estimates baseline odds.

Hypothesis Tests and Interpretation

• Age (age):

The odds ratio is 1.0316. This implies that, holding treatment, BMI, and tumor size constant, each additional year of age multiplies the odds of death by 1.0316, or a 3.16% increase in the odds of death per year. This effect is statistically significant (z = 4.30, p < 0.001).

Comparison with Recurrence: In the recurrence model, age had an odds ratio of 0.9744 (i.e., each additional year was associated with a 2.56% decrease in the odds of recurrence). Hence, while older age appears protective against recurrence, it increases the risk of death.

• Treatment (trt):

The odds ratio is 0.723, indicating that tamoxifen reduces the odds of death by about 27.7% compared to placebo (since $1-0.723 \approx 0.277$), controlling for age, BMI, and tumor size. This effect is statistically significant (z = -2.38, p = 0.017).

Non-Cancer Death (ned as Outcome) Stata Output

logit ned trt age bmi tumsiz, or

Iteration 0: log likelihood = -274.67427 Iteration 1: log likelihood = -245.29402 Iteration 2: log likelihood = -239.21336 Iteration 3: log likelihood = -239.1413 Iteration 4: log likelihood = -239.14128

Logistic regression Number of obs = 1,042 LR chi2(4) = 71.07 Prob > chi2 = 0.0000 Log likelihood = -239.14128 Pseudo R2 = 0.1294

ned | Odds Ratio Std. Err. [95\% Conf. Interval] P>|z| Z .270827 trt | 1.097409 0.38 0.706 .6765539 1.78006 age | 1.141015 .022213 6.78 0.000 1.098298 1.185393 .9839115 .0230083 -0.69 0.488 .939834 1.030056 bmi | tumsiz | 1.017106 .0103739 1.66 0.096 .9969753 1.037643 .0000321 .0000425 -7.810.000 2.39e-06 .0004309 _cons |

Note: _cons estimates baseline odds.

Hypothesis Tests and Interpretation

• Age (age):

The odds ratio is 1.1410. This indicates that, after adjusting for treatment, BMI, and tumor size, each additional year of age multiplies the odds of non-cancer death by 1.1410, or each additional year of age is associated with a 14.10% increase of odds of non-cancer death. This effect is statistically significant (z = 6.78, p < 0.001).

• Treatment (trt):

The odds ratio is 1.0974, suggesting that tamoxifen is associated with a 9.74% increase in the odds of non-cancer death relative to placebo. However, this effect is not statistically significant (z = 0.38, p = 0.706).

In summary, age is a significant predictor in both models. In the overall survival model (using dead as the outcome), each additional year of age increases the odds of death by about 3.16%, holding treatment, BMI, and

tumor size constant. In contrast, in the non-cancer death model (using ned as the outcome), the effect of age is more pronounced, with each additional year increasing the odds by approximately 14.10%.

This stronger association in the non-cancer death model suggests that older age may be more closely linked to deaths from causes other than cancer. Since mortality is inevitable and the risk of dying from other diseases generally increases with age, this result may indicate that, while cancer-related mortality is influenced by multiple factors, the overall vulnerability associated with aging plays a more substantial role in mortality. Regarding treatment, tamoxifen shows a protective effect in the overall survival model by reducing the odds of death by about 27.7%, but it is not significantly related to non-cancer death, which further supports the idea that its benefits are primarily linked to cancer-specific outcomes.

(e)

We fit the logistic regression model for endometrial cancer (endo) using treatment (trt) as the sole predictor. The Stata output is shown below.

Logistic Regression Output

logit endo trt, or
Iteration 0: log likelihood = -74.243285
Iteration 1: log likelihood = -71.973465
Iteration 2: log likelihood = -71.766957
Iteration 3: log likelihood = -71.766622
Iteration 4: log likelihood = -71.766622

Logistic regression	Number of obs	=	1,042
	LR chi2(1)	=	4.95
	Prob > chi2	=	0.0260
Log likelihood = -71.766622	Pseudo R2	=	0.0334

			Std. Err.			[95% Conf.	Interval]
trt	İ	3.738703	2.446306 .0033469	2.02	0.044	1.036963 .0018582	

Note: _cons estimates baseline odds.

Interpretation of Logistic Regression

Controlling for baseline odds, the odds ratio for treatment is 3.74. This indicates that patients receiving tamoxifen (trt = 1) have approximately 3.74 times higher odds of developing endometrial cancer compared to those receiving placebo (trt = 0). The result is statistically significant (p = 0.044).

Predicted Probabilities

The predicted probabilities for endometrial cancer were computed using the logistic regression model and stored in the variable prob_d. The output from the tabulate prob_d command is as follows:

tabulate prob_d

Cum.	Percent	Freq.	Pr(endo)
50.10	50.10	522	.0057471
100.00	49.90	520	.0211538

These predicted probabilities correspond to the two treatment groups:

- For the placebo group (trt = 0), the predicted probability of endometrial cancer is approximately 0.00575 (or 0.57%).
- For the tamoxifen group (trt = 1), the predicted probability is about 0.02115 (or 2.12%).

These predictions are calculated by applying the logistic regression model:

$$p = \frac{\exp(L)}{1 + \exp(L)},$$

where L is the linear predictor (i.e., $L = \beta_0 + \beta_1 \cdot \text{trt}$).

2×2 Table and Odds Ratio Calculation

The following 2×2 table was generated to summarize the distribution of endometrial cancer by treatment group:

tabulate endo trt

endo	 	trt O	1	Total
0		519 3	509 11	1,028 14
Total		522	520	1,042

For the placebo group (trt = 0):

$$Odds_0 = \frac{Number\ of\ endo}{Number\ of\ endo} = \frac{3}{519}.$$

For the tamoxifen group (trt = 1):

$$Odds_1 = \frac{Number\ of\ endo}{Number\ of\ endo} = \frac{1}{509}.$$

Thus, the odds ratio is calculated as:

$$OR = \frac{Odds_1}{Odds_0} = \frac{\frac{11}{509}}{\frac{3}{519}} = \frac{11 \times 519}{3 \times 509} \approx 3.738.$$

This is consistent with the logistic regression output.

Overall Conclusion

Both the logistic regression analysis and the 2×2 table indicate that tamoxifen treatment is associated with a significantly increased risk of endometrial cancer. The odds ratio of approximately 3.74 suggests that tamoxifen increases the odds of developing endometrial cancer by 3.74 times compared to placebo. However, the absolute risk remains very low, as evidenced by the predicted probabilities of 0.57% for the placebo group and 2.12% for the tamoxifen group.

(f)

We use the logistic regression model (omitting BMI) given by:

$$logit(p) = \beta_0 + \beta_{trt} \cdot trt + \beta_{age} \cdot age + \beta_{tumsiz} \cdot tumsiz,$$

. logit recur trt age tumsiz

Iteration 0: log likelihood = -602.37472
Iteration 1: log likelihood = -584.99952
Iteration 2: log likelihood = -584.84224
Iteration 3: log likelihood = -584.84222

Logistic regression Number of obs = 1,042 LR chi2(3) = 35.07 Prob > chi2 = 0.0000 Log likelihood = -584.84222 Pseudo R2 = 0.0291

recur	Coef.	Std. Err.				Interval]
trt age tumsiz	4916501 0236281 .0197753 .0222022	.1439548 .0070497 .0060813	-3.42	0.001 0.001 0.001	7737963 0374453 .0078561	

The estimated coefficients are:

$$\beta_0 = 0.0222022$$
, $\beta_{\text{trt}} = -0.4916501$, $\beta_{\text{age}} = -0.0236281$, $\beta_{\text{tumsiz}} = 0.0197753$.

The predicted probability is computed as:

$$p = \frac{\exp(L)}{1 + \exp(L)},$$

where L is the linear predictor.

Case 1: Age = 50, Tumor Size = 30 mm, Tamoxifen (trt = 1)

$$L_1 = 0.0222022 + (-0.4916501)(1) + (-0.0236281)(50) + (0.0197753)(30).$$

Thus,

$$L_1 = 0.0222022 - 0.4916501 - 1.181405 + 0.593259 \approx -1.057594.$$

The predicted probability is:

$$p_1 = \frac{\exp(-1.057594)}{1 + \exp(-1.057594)} \approx \frac{0.347}{1.347} \approx 0.2576 \quad (25.8\%).$$

Case 2: Age = 50, Tumor Size = 30 mm, Placebo (trt = 0)

$$L_2 = 0.0222022 + (-0.4916501)(0) + (-0.0236281)(50) + (0.0197753)(30).$$

Thus,

$$L_2 = 0.0222022 - 0 - 1.181405 + 0.593259 \approx -0.565944.$$

The predicted probability is:

$$p_2 = \frac{\exp(-0.565944)}{1 + \exp(-0.565944)} \approx \frac{0.568}{1.568} \approx 0.3622$$
 (36.2%).

Case 3: Age = 65, Tumor Size = 10 mm, Tamoxifen (trt = 1)

$$L_3 = 0.0222022 + (-0.4916501)(1) + (-0.0236281)(65) + (0.0197753)(10).$$

Thus,

$$L_3 = 0.0222022 - 0.4916501 - 1.5358265 + 0.197753 \approx -1.807521.$$

The predicted probability is:

$$p_3 = \frac{\exp(-1.807521)}{1 + \exp(-1.807521)} \approx \frac{0.164}{1.164} \approx 0.1409 \quad (14.1\%).$$

Case 4: Age = 65, Tumor Size = 10 mm, Placebo (trt = 0)

$$L_4 = 0.0222022 + (-0.4916501)(0) + (-0.0236281)(65) + (0.0197753)(10).$$

Thus,

$$L_4 = 0.0222022 - 0 - 1.5358265 + 0.197753 \approx -1.315871.$$

The predicted probability is:

$$p_4 = \frac{\exp(-1.315871)}{1 + \exp(-1.315871)} \approx \frac{0.268}{1.268} \approx 0.2114$$
 (21.1%).

We can check whether it is consistent with stata output:

- . * Case 1: age = 50, tumor size = 30 mm, tamoxifen (trt = 1)
- . margins, at(trt=1 age=50 tumsiz=30)

Adjusted predictions Number of obs = 1,042

Model VCE : OIM

Expression : Pr(recur), predict()

at : trt = 1 age = 50 tumsiz = 30

^{. *} Case 2: age = 50, tumor size = 30 mm, placebo (trt = 0)

[.] margins, at(trt=0 age=50 tumsiz=30)

Adjusted predi				Number o	of obs =	1,042
Expression : at :	Pr(recur), trt age tumsiz	=	0 50 30			
	Margin	Delta-method Std. Err.	z	P> z	[95% Conf.	Interval]
•		.0242055		0.000	.314731	.4096148
* Case 3: ag . margins, at(trt=1 age=65		m, tamox			
Adjusted predi Model VCE :				Number o	of obs =	1,042
Expression : at :	trt age		1 65 10			
		Delta-method Std. Err.		P> z	[95% Conf.	Interval]
_cons	.1409377	.0192462	7.32	0.000	.1032158	.1786597
. * Case 4: ag . margins, at(Adjusted predi Model VCE : Expression : at :	trt=0 age=65 ctions OIM	tumsiz=10)	m, place 0 65 10		= 0) of obs =	1,042
 		Delta-method Std. Err.	z	P> z	[95% Conf.	Intervall
		.0254104				

As a result, they are consistent.

Summary of Predicted Probabilities:

Case	\mathbf{Age}	Tumor Size (mm)	Treatment	Probability
1	50	30	Tamoxifen $(trt = 1)$	25.8%
2	50	30	Placebo $(trt = 0)$	36.2%
3	65	10	Tamoxifen $(trt = 1)$	14.1%
4	65	10	Placebo $(trt = 0)$	21.1%

Table 1: Predicted probabilities of recurrence for various covariate patterns.

(g)

Now we compare the logistic regression results for three endpoints—breast cancer recurrence, breast cancer death, and endometrial cancer—and discusses the argument supporting the continued use of tamoxifen based on both relative and absolute risks.

1. Breast Cancer Recurrence

Logistic Regression Output:

logit recur trt age tumsiz

Iteration 0: log likelihood = -602.37472
Iteration 1: log likelihood = -584.99952
Iteration 2: log likelihood = -584.84224
Iteration 3: log likelihood = -584.84222

Logistic regression Number of obs = 1,042 LR chi2(3) = 35.07 Prob > chi2 = 0.0000 Log likelihood = -584.84222 Pseudo R2 = 0.0291

Predicted Probabilities by Treatment (using margins):

margins, at(trt=(0 1))

Predictive margins Number of obs = 1,042

Model VCE : OIM

Expression : Pr(recur), predict()

1._at : trt = 0 2._at : trt = 1

 	Margin	Delta-method Std. Err.			Interval]
_at 1 2	.310867 .2180468	.0199772 .0180181	15.56 12.10	.2717124 .182732	.3500215

Interpretation: Patients on placebo have a predicted recurrence probability of about 31.1%, whereas those on tamoxifen have about 21.8%. This indicates a substantial reduction in the absolute risk of recurrence with tamoxifen treatment.

2. Breast Cancer Death

Logistic Regression Output (including BMI):

logit dead trt age bmi tumsiz

Logistic regression Number of obs = 1,042 LR chi2(4) = 52.75 Prob > chi2 = 0.0000 Log likelihood = -629.48058 Pseudo R2 = 0.0402

 dead |
 Coef.
 Std. Err.
 z
 P>|z|
 [95% Conf. Interval]

 trt |
 -.3244105
 .1364825
 -2.38
 0.017
 -.5919113
 -.0569098

 age |
 .0311148
 .0072339
 4.30
 0.000
 .0169367
 .045293

 bmi |
 .022794
 .0125463
 1.82
 0.069
 -.0017963
 .0473842

 tumsiz |
 .027196
 .0059672
 4.56
 0.000
 .0155005
 .0388915

 _cons |
 -3.539813
 .5040185
 -7.02
 0.000
 -4.527671
 -2.551954

Predicted Probabilities by Treatment (using margins):

margins, at(trt=(0 1))

Predictive margins Number of obs = 1,042

Model VCE : OIM

Expression : Pr(dead), predict()

1._at : trt = 0 2._at : trt = 1

 	-	Delta-method Std. Err.	z	P> z	[95% Conf.	Interval]
_at 1 2	.3574313	.0205736 .0193716	17.37 14.96	0.000	.3171079 .2519163	.3977548 .3278515

Interpretation: The predicted probability of death is approximately 35.7% for the placebo group and 28.9% for the tamoxifen group. It is also a substantial reduction.

3. Endometrial Cancer

Logistic Regression Output (including age and tumor size):

logit endo trt age tumsiz

Iteration 0: log likelihood = -74.243285
Iteration 1: log likelihood = -71.575745
Iteration 2: log likelihood = -71.288921
Iteration 3: log likelihood = -71.288498
Iteration 4: log likelihood = -71.288498

Logistic regression Number of obs = 1,042 LR chi2(3) = 5.91 Prob > chi2 = 0.1161 Log likelihood = -71.288498 Pseudo R2 = 0.0398

Predicted Probabilities by Treatment (using margins):

margins, at(trt=(0 1))

Predictive margins Number of obs = 1,042

Model VCE : OIM

Expression : Pr(endo), predict()

1._at : trt = (2._at : trt = 1

| Delta-method

	Margin	Std. Err.	z	P> z	[95% Conf.	Interval]
,	 .005822 .0208875			0.082 0.001	0007474 .0086676	

Interpretation: For endometrial cancer, the predicted probability is very low in both groups: about 0.58% for the placebo group and 2.09% for the tamoxifen group. Although tamoxifen is associated with a relative increase in risk (with an estimated odds ratio of approximately 3.29 from the regression coefficients), the absolute risk remains very small.

Therefore, while tamoxifen increases the relative risk of endometrial cancer (with a predicted probability of approximately 2.1% versus 0.6% for placebo), the absolute risk for this adverse outcome is extremely small. In contrast, tamoxifen significantly reduces the risk of breast cancer recurrence and death, with absolute reductions of approximately 9.3 percentage points (31.1% to 21.8%) for recurrence and 7 percentage points (35.7% to 28.9%) for death. Given that breast cancer events and mortality occur at much higher rates than endometrial cancer, the substantial benefits in lowering recurrence and mortality far outweigh the modest absolute increase in the risk of endometrial cancer. This favorable benefit–risk profile supports the continued use of tamoxifen in appropriate patients.

Question 2

(a)

We first create a binary outcome variable, fail, where

$$\mathtt{fail} = \begin{cases} 1, & \text{if damaged} > 0 & (\text{any damage}), \\ 0, & \text{if damaged} = 0 & (\text{no damage}). \end{cases}$$

This is done in Stata as follows:

```
gen fail = (damaged > 0)
```

Next, we fit a logistic regression model predicting the probability of an O-ring failure by temperature (temp):

Stata Output

```
Iteration 0:
            log\ likelihood = -14.133576
Iteration 1:
            log likelihood = -10.302864
            log\ likelihood = -10.157825
Iteration 2:
            log\ likelihood = -10.157596
Iteration 3:
Iteration 4:
            log\ likelihood = -10.157596
Logistic regression
                                        Number of obs
                                                               23
                                        LR chi2(1)
                                                             7.95
                                        Prob > chi2
                                                            0.0048
Log likelihood = -10.157596
                                       Pseudo R2
                                                            0.2813
      fail | Odds Ratio Std. Err. z P>|z|
                                                [95% Conf. Interval]
```

temp | 0.7928171 0.0858118 -2.14 0.032

0.6412715 0.9801761

_cons 341231	5 2.52e+07	2.04	0.041	1.787897	6.51e+12
----------------	------------	------	-------	----------	----------

Note: _cons estimates baseline odds.

Predicted Probabilities

We compute the predicted probabilities of failure as follows:

tabulate prob_f

Pr(fail)	Freq.	Percent	Cum.
0.0227033	 1	4.35	4.35
0.0356414	1	4.35	8.70
0.0445405	1	4.35	13.04
0.0690441	2	8.70	21.74
0.0855436	2	8.70	30.43
0.129546	1	4.35	34.78
0.1580491	1	4.35	39.13
0.2299683	4	17.39	56.52
0.2736211	1	4.35	60.87
0.3220941	1	4.35	65.22
0.3747243	3	13.04	78.26
0.4304931	1	4.35	82.61
0.602681	1	4.35	86.96
0.8288448	1	4.35	91.30
0.8593166	1	4.35	95.65
0.9392478	1	4.35	100.00
Total	23	100.00	

Interpretation

The logistic regression model yields an estimated odds ratio for temperature of approximately 0.7928 (95% CI: 0.6413 to 0.9802) with p=0.032. This indicates that for each one–degree Fahrenheit increase in launch temperature, the odds of an O–ring failure decrease by about 20.7% (since $1-0.7928\approx0.2072$). Or each one-degree Fahrenheit increase multiply the odds of an O-ring failure by 0.793. This effect is significant.

The predicted probabilities (prob_f) for O-ring failure across the 23 observations range from roughly 2.3% to 93.9%. These predictions are obtained by applying the logistic function

$$p = \frac{\exp(L)}{1 + \exp(L)},$$

where $L = \beta_0 + \beta_1 \cdot \text{temp}$.

(b)

After dropping observation Flight #18:

Stata Output

drop if flightno == 18
logit fail temp, or

Iteration 0: log likelihood = -12.890958

Logistic regression	Number of obs	=	22
	LR chi2(1)	=	11.40
	Prob > chi2	=	0.0007
Log likelihood = -7.1884884	Pseudo R2	=	0.4424

fail	Odds Ratio	Std. Err.	z	P> z	[95% Conf.	Interval]
· .	0.6969644 1.46e+10				0.4940968 1.238225	0.9831259 1.72e+20

Note: _cons estimates baseline odds.

Interpretation

With flight #18 excluded, the estimated odds ratio for temperature is approximately 0.697 (95% CI: 0.494 to 0.983, p=0.040). This indicates that for each one-degree Fahrenheit increase in temperature, the odds of an O-ring failure decrease by about 30.3% (calculated as $1-0.697 \approx 0.303$). Or each one-degree Fahrenheit increase multiply the odds of an O-ring failure by 0.697. The statistical significance (p = 0.040) suggests that this effect is significant.

(c)

Using the fitted logistic regression model

$$logit(p) = \beta_0 + \beta_1 \cdot temp,$$

logit fail temp

Iteration 0: log likelihood = -12.890958
Iteration 1: log likelihood = -7.6133038
Iteration 2: log likelihood = -7.1953417
Iteration 3: log likelihood = -7.1885097
Iteration 4: log likelihood = -7.1884884
Iteration 5: log likelihood = -7.1884884

Logistic regression	Number of obs	=	22
	LR chi2(1)	=	11.40
	Prob > chi2	=	0.0007
Log likelihood = -7.1884884	Pseudo R2	=	0.4424

fail		Std. Err.			2 - 10	. Interval]
temp	361021	.1755149	-2.06	0.040	7050238 .2136786	

we have the estimated coefficients

$$\beta_0 = 23.4033$$
 and $\beta_1 = -0.361021$,

we calculate the linear predictor for a launch temperature of 31°F:

$$L = 23.4033 + (-0.361021 \times 31) \approx 23.4033 - 11.19165 = 12.21165.$$

The predicted probability of an O-ring failure is given by

$$P(Y=1|X) = \frac{\exp(L)}{1 + \exp(L)}.$$

Substituting the computed value of L,

$$P(Y=1|X) \approx \frac{\exp(12.21165)}{1 + \exp(12.21165)} \approx \frac{201118.59}{201119.59} \approx 0.999995.$$

Interpretation: At a launch temperature of 31°F, the model predicts an almost certain probability of an O-ring failure (99.99%). Based on this result, I would have advised against launching on that day.

(d)

Using the logistic regression model based on all launches except flight #18, we predicted the probability of damage (O-ring failure) and classified an observation as "damaged" if the predicted probability was ≥ 0.50 :

. logit fail temp

Number of obs	=	22
LR chi2(1)	=	11.40
Prob > chi2	=	0.0007
Pseudo R2	=	0.4424

Log likelihood = -7.1884884

fail	Coef.			• •	2	. Interval]
temp		.1755149	-2.06	0.040	7050238 .2136786	

. predict phat

(option pr assumed; Pr(fail))

. list fail temp phat

	 	fail	temp	phat
1.	1	1	53	.9862
2.		1	57	.9440178
3.		1	58	.9215857

4.	1	63	.6590322
5.	0	66	.3955413
6.	0	67	.3132219
7.	0	68	.2411985
8.	0	69	.1813629
9.	1	70	.1337545
10.	l 0	72	.0697715
11.	l 0	73	.0496786
12.	l 0	75	.0247645
13.	l 0	76	.0173905
14.	l 0	78	.0085238
15.	l 0	79	.0059562
16.	l 0	81	.0029022
17.	1 1	70	.1337545
18.	l 0	67	.3132219
19.	l 0	70	.1337545
20.	l 0	76	.0173905
21.	0	67	.3132219
22.	I 0	70	.1337545
-	+		+

The following 2×2 table summarizes the predicted classification versus the actual damage status:

estat classification

Logistic model for fail

		True		
Classified	l D	~D		Total
+	4	0	-+- 	4
-	2	16		18
Total	I 6	16		22
Classified	+ if predic	ted Pr(D) >= .5	,	

True D defined as fail != 0 -----Pr(+| D) 66.67% Sensitivity Pr(+|D) = 66.67%Specificity $Pr(-|^{\sim}D) = 100.00\%$ Positive predictive value Pr(D|+) = 100.00%Negative predictive value $Pr(^{\sim}D|-) = 88.89\%$ Sensitivity

0.00% 33.33% False + rate for classified + $Pr(^{\sim}D| +)$ False - rate for classified - $Pr(^{\sim}D| -)$ 0.00%

11.11%

Correctly classified

From the table, the number of correctly classified observations is the sum of true positives and true negatives:

Correctly Classified =
$$4 + 16 = 20$$
 (out of 22 observations),

which corresponds to an overall accuracy of approximately 90.91%. Therefore, based on the model (excluding flight #18), 20 out of 22 launches were correctly classified as either damaged or not damaged when using a threshold of 0.50 for the predicted probability. This indicates that the model performs well in distinguishing between launches with and without O-ring damage.

(e)

When deciding on future launches using the predicted probability of O-ring damage (based on temperature), the most critical consideration is the risk of a false negative—i.e., predicting that no damage will occur when, in fact, damage is present. A false negative could lead to a launch that is actually unsafe, with potentially catastrophic consequences.

Below are three classification tables generated with different cut-points.

Classification Table with Cutoff = 0.5

Logistic model for fail

		True		
Classified	D	~D	 	Total
+	4 2	0 16		4
Total	6	 16	 	22

Classified + if predicted Pr(D) >= .5True D defined as fail != 0

_____ Sensitivity Pr(+| D) 66.67% Specificity Pr(-|~D) 100.00% Positive predictive value Pr(D| +) 100.00% Pr(~D| -) Negative predictive value 88.89% _____ False + rate for true ~D Pr(+|~D) 0.00% False - rate for true D Pr(-| D) 33.33% False + rate for classified + Pr(~D| +) 0.00% False - rate for classified - Pr(D|-) 11.11% 90.91% Correctly classified

Classification Table with Cutoff = 0.67

Logistic model for fail

		True		
Classified	D	~D	- 1	Total
+	3	0	 	3
- i	3	16	i	19

Total		6		6	22
	_	predicted Pr s fail != 0	r(D) >=	. 67	
Sensitivit Specificit Positive p Negative p	ty oredict:		Pr(Pr(+ D) - ~D) D +) ~D -)	100.00%
	ate for ate for		Pr(+ Pr(+ ~D) - D) ~D +) D -)	
Correctly	classi:	fied 			86.36%

Classification Table with Cutoff = 0.33

Logistic model for fail

True				
Classified	D D	~D	Total	
+	 4	 1	 5	
-	2	15	17	
Total	6	16	22	
	+ if predicted Pr(D) >= .33		
Sensitivity		Pr(+ D)	66.67%	
Specificity		Pr(- ~D)	93.75%	
Positive pre	edictive value	Pr(D +)	80.00%	
Negative pre	edictive value	Pr(~D -)	88.24%	
False + rate	e for true ~D	Pr(+ ~D)	6.25%	
False - rate	e for true D	Pr(- D)	33.33%	
False + rate	e for classified +	Pr(~D +)	20.00%	

False - rate for classified - Pr(D| -) 11.76%

Comparison and Analysis

• Cutoff = 0.5:

Correctly classified

- Sensitivity: 66.67% (i.e., two-thirds of the true damage cases are detected)
- Specificity: 100% (all non-damaged cases are correctly identified)
- PPV and NPV: 100% and 88.89%, respectively

86.36%

- Overall Accuracy: 90.91%

• Cutoff = 0.67:

- Sensitivity: Drops to 50% (a 16.67 percentage point decrease, meaning half of the true damage cases are missed)

- **Specificity:** Remains at 100%

- NPV: Decreases to 84.21%

- Overall Accuracy: Declines to 86.36%

• Cutoff = 0.33:

- **Sensitivity:** Remains at 66.67% (same as the 0.5 cutoff)

- **Specificity:** Decreases to 93.75% (a slight increase in false positives, that some none-damage cases are classified as damaged)

- $\mathbf{PPV:}$ Drops to 80.00%

- Overall Accuracy: 86.36%

Discussion:

The key metric in this context is **sensitivity**, as failing to identify a damaged O–ring (a false negative) could have catastrophic implications. Comparing the three cut-points:

- Increasing the cutoff to 0.67 improves specificity to 100% but at the cost of reducing sensitivity to only 50%. This means that half of the actual damage cases would be missed—a risk that is unacceptable for launch safety.
- Lowering the cutoff to 0.33 does not improve sensitivity compared to 0.5 (both remain at 66.67%) but does reduce specificity (from 100% to 93.75%) and lowers the positive predictive value.
- The cutoff of 0.5 strikes a balance by achieving high sensitivity (66.67%) and perfect specificity, resulting in the highest overall accuracy (90.91%).

Conclusion: For deciding on future launches, the most relevant quantity is sensitivity because missing a potential O-ring damage (false negative) is far more dangerous than a false positive. Based on the comparisons, a cutoff of 0.5 is the most reasonable choice, as it minimizes the risk of false negatives while maintaining perfect specificity.